Alterations in Lipid and Inositol Metabolisms in Two Dopaminergic Disorders

Background Serum metabolite profiling can be used to identify pathways involved in the pathogenesis of and potential biomarkers for a given disease. Both restless legs syndrome (RLS) and Parkinson`s disease (PD) represent movement disorders for which currently no blood-based biomarkers are available and whose pathogenesis has not been uncovered conclusively. We performed unbiased serum metabolite profiling in search of signature metabolic changes for both diseases. Methods 456 metabolites were quantified in serum samples of 1272 general population controls belonging to the KORA cohort, 82 PD cases and 95 RLS cases by liquid-phase chromatography and gas chromatography separation coupled with tandem mass spectrometry. Genetically determined metabotypes were calculated using genome-wide genotyping data for the 1272 general population controls. Results After stringent quality control, we identified decreased levels of long-chain (polyunsaturated) fatty acids of individuals with PD compared to both RLS (PD vs. RLS: p = 0.0001 to 5.80x10-9) and general population controls (PD vs. KORA: p = 6.09x10-5 to 3.45x10-32). In RLS, inositol metabolites were increased specifically (RLS vs. KORA: p = 1.35x10-6 to 3.96x10-7). The impact of dopaminergic drugs was reflected in changes in the phenylalanine/tyrosine/dopamine metabolism observed in both individuals with RLS and PD. Conclusions A first discovery approach using serum metabolite profiling in two dopamine-related movement disorders compared to a large general population sample identified significant alterations in the polyunsaturated fatty acid metabolism in PD and implicated the inositol metabolism in RLS. These results provide a starting point for further studies investigating new perspectives on factors involved in the pathogenesis of the two diseases as well as possible points of therapeutic intervention.

[1]  Jiali Han,et al.  Prospective study of obesity, hypertension, high cholesterol, and risk of restless legs syndrome , 2014, Movement disorders : official journal of the Movement Disorder Society.

[2]  John P. Overington,et al.  An atlas of genetic influences on human blood metabolites , 2014, Nature Genetics.

[3]  R. Hotchkiss,et al.  Development of an immunoassay for the kidney-specific protein myo-inositol oxygenase, a potential biomarker of acute kidney injury. , 2014, Clinical chemistry.

[4]  Derick R. Peterson,et al.  Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.

[5]  Li-Fang Hu,et al.  Elevated homocysteine levels in levodopa‐treated idiopathic Parkinson's disease: a meta‐analysis , 2013, Acta neurologica Scandinavica.

[6]  Christian Gieger,et al.  Metabolomic markers reveal novel pathways of ageing and early development in human populations , 2013, International journal of epidemiology.

[7]  C. Gieger,et al.  Human serum metabolic profiles are age dependent , 2012, Aging cell.

[8]  Christian Gieger,et al.  Mining the Unknown: A Systems Approach to Metabolite Identification Combining Genetic and Metabolic Information , 2012, PLoS genetics.

[9]  Y. Yaari,et al.  α‐Synuclein Neuropathology is Controlled by Nuclear Hormone Receptors and Enhanced by Docosahexaenoic Acid in A Mouse Model for Parkinson's Disease , 2012, Brain pathology.

[10]  Chuong B. Do,et al.  Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.

[11]  H. Neels,et al.  Influence of separator gel in Sarstedt S-Monovette® serum tubes on various therapeutic drugs, hormones, and proteins. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[12]  C. Cantor,et al.  Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease. , 2011, Toxicology letters.

[13]  P. Tariot,et al.  A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease , 2011, Neurology.

[14]  C. Gieger,et al.  Human metabolic individuality in biomedical and pharmaceutical research , 2011, Nature.

[15]  C. Gieger,et al.  Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1 , 2011, PLoS genetics.

[16]  Nicholas Eriksson,et al.  Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease , 2011, PLoS genetics.

[17]  F. Cicchetti,et al.  Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease , 2011, Journal of Lipid Research.

[18]  Fabian J. Theis,et al.  Gaussian graphical modeling reconstructs pathway reactions from high-throughput metabolomics data , 2011, BMC Systems Biology.

[19]  Cai Song,et al.  Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. , 2010, European journal of pharmacology.

[20]  Christian Gieger,et al.  A genome-wide perspective of genetic variation in human metabolism , 2010, Nature Genetics.

[21]  Rima Kaddurah-Daouk,et al.  Metabolomics tools for identifying biomarkers for neuropsychiatric diseases , 2009, Neurobiology of Disease.

[22]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[23]  J. Whelan.  (n-6) and (n-3) Polyunsaturated fatty acids and the aging brain: food for thought. , 2008, The Journal of nutrition.

[24]  Christian Gieger,et al.  Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum , 2008, PLoS genetics.

[25]  T. Kawanami,et al.  N‐terminal region of α‐synuclein is essential for the fatty acid‐induced oligomerization of the molecules , 2008, FEBS letters.

[26]  C. Gieger,et al.  PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome , 2008, Nature Genetics.

[27]  Hans-Werner Mewes,et al.  Bioinformatics analysis of targeted metabolomics--uncovering old and new tales of diabetic mice under medication. , 2008, Endocrinology.

[28]  W. Matson,et al.  Metabolomic profiling to develop blood biomarkers for Parkinson's disease. , 2008, Brain : a journal of neurology.

[29]  D. Selkoe,et al.  Polyunsaturated Fatty Acids Induce α-Synuclein-Related Pathogenic Changes in Neuronal Cells , 2007 .

[30]  Christian Gieger,et al.  Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions , 2007, Nature Genetics.

[31]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.

[32]  C. Gieger,et al.  KORA-gen - Resource for Population Genetics, Controls and a Broad Spectrum of Disease Phenotypes , 2005, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[33]  U. John,et al.  Sex and the risk of restless legs syndrome in the general population. , 2004, Archives of internal medicine.

[34]  Richard P Allen,et al.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. , 2003, Sleep medicine.

[35]  D. Maraganore,et al.  Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.

[36]  R. Belmaker,et al.  Inositol treatment of obsessive-compulsive disorder. , 1996, The American journal of psychiatry.

[37]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[38]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[39]  K. Blennow,et al.  Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. , 2014, Journal of Parkinson's disease.

[40]  C. Tanner,et al.  Dietary fat intake, pesticide use, and Parkinson's disease. , 2014, Parkinsonism & related disorders.

[41]  D. Selkoe,et al.  Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. , 2007, The American journal of pathology.